M. Houghton. The long and winding road leading to the identification of the hepatitis C virus. „Journal of Hepatology”. 51 (5), s. 939–948, listopad 2009. DOI: 10.1016/j.jhep.2009.08.004. PMID: 19781804.
HR Rosen. Clinical practice. Chronic hepatitis C infection. „The New England Journal of Medicine”. 364 (25), s. 2429–2438, 2011-06-23. DOI: 10.1056/NEJMcp1006613. PMID: 21696309.
Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. „Digestive and Liver Disease”. 39 (1), s. 2–17, styczeń 2007. DOI: 10.1016/j.dld.2006.06.008. PMID: 16884964.
Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. „Liver Int.”, grudzień 2011. DOI: 10.1111/j.1478-3231.2011.02684.x. PMID: 22142261.
X Xia, J. Luo, J. Bai, R. Yu. Epidemiology of HCV infection among injection drug users in China: systematic review and meta-analysis. „Public health”. 122 (10), s. 990–1003, październik 2008. DOI: 10.1016/j.puhe.2008.01.014. PMID: 18486955.
Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission?. „Hepatology”. 52 (4), s. 1497–1505, czerwiec 2010. DOI: 10.1002/hep.23808. PMID: 20635398.
Lock G, Dirscherl M, Obermeier F, et al.. Hepatitis C –contamination of toothbrushes: myth or reality?. „J. Viral Hepat.”. 13 (9), s. 571–573, wrzesień 2006. DOI: 10.1111/j.1365-2893.2006.00735.x. PMID: 16907842.
J Halliday, P. Klenerman, E. Barnes. Vaccination for hepatitis C virus: closing in on an evasive target. „Expert review of vaccines”. 10 (5), s. 659–672, maj 2011. DOI: 10.1586/erv.11.55. PMID: 21604986.
J Torresi, D. Johnson, H. Wedemeyer. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. „Journal of hepatology”. 54 (6), s. 1273–1285, czerwiec 2011. DOI: 10.1016/j.jhep.2010.09.040. PMID: 21236312.
Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. „Ann Pharmacother”. 45 (9), s. 1085–1093, wrzesień 2011. DOI: 10.1345/aph.1P744. PMID: 21828346.
Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. „Ann Pharmacother”. 45 (5), s. 639–648, maj 2011. DOI: 10.1345/aph.1P430. PMID: 21558488.
Ghany MG, Nelson DR, Strader DB, Thomas DL i inni. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. „Hepatology”. 54 (4), s. 1433–1444, październik 2011. DOI: 10.1002/hep.24641. PMID: 21898493. PMCID: PMC3229841.
Fung J, Lai CL, Hung I, et al.. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. „The Journal of Infectious Diseases”. 198 (6), s. 808–812, wrzesień 2008. DOI: 10.1086/591252. PMID: 18657036.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. „Science”. 244 (4902), s. 359–362, kwiecień 1989. DOI: 10.1126/science.2523562. PMID: 2523562.
Kuo G, Choo QL, Alter HJ, et al.. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. „Science”. 244 (4902), s. 362–364, kwiecień 1989. DOI: 10.1126/science.2496467. PMID: 2496467.
A.C. El Khoury, W.K. Klimack, C. Wallace, H. Razavi. Economic burden of hepatitis C-associated diseases in the United States. „Journal of Viral Hepatitis”, 2011-12-01. DOI: 10.1111/j.1365-2893.2011.01563.x.
J Ahn, SL Flamm. Hepatitis C therapy: other players in the game. „Clinics in liver disease”. 15 (3), s. 641–656, sierpień 2011. DOI: 10.1016/j.cld.2011.05.008. PMID: 21867942.
M FM.F.VescioM FM.F. i inni, Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis, „Journal of epidemiology and community health”, 62 (4), 2008, s. 305–13, DOI: 10.1136/jech.2006.051599, PMID: 18339822.
M. Houghton. The long and winding road leading to the identification of the hepatitis C virus. „Journal of Hepatology”. 51 (5), s. 939–948, listopad 2009. DOI: 10.1016/j.jhep.2009.08.004. PMID: 19781804.
HR Rosen. Clinical practice. Chronic hepatitis C infection. „The New England Journal of Medicine”. 364 (25), s. 2429–2438, 2011-06-23. DOI: 10.1056/NEJMcp1006613. PMID: 21696309.
S Mueller, G Millonig, HK Seitz. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. „World journal of gastroenterology: WJG”. 15 (28), s. 3462–3471, 2009-07-28. PMID: 19630099.
MJ Alter. Epidemiology of hepatitis C virus infection. „World journal of gastroenterology: WJG”. 13 (17), s. 2436–2441, 2007-05-07. PMID: 17552026.
R Ozaras, V. Tahan. Acute hepatitis C: prevention and treatment. „Expert review of anti-infective therapy”. 7 (3), s. 351–361, kwiecień 2009. PMID: 19344247.
Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. „Digestive and Liver Disease”. 39 (1), s. 2–17, styczeń 2007. DOI: 10.1016/j.dld.2006.06.008. PMID: 16884964.
KS Louie, Micallef, JM, Pimenta, JM, Forssen, UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. „Journal of viral hepatitis”. 18 (1), s. 1–7, styczeń 2011. PMID: 20796208.
Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. „Liver Int.”, grudzień 2011. DOI: 10.1111/j.1478-3231.2011.02684.x. PMID: 22142261.
A Maheshwari, Thuluvath, PJ. Management of acute hepatitis C. „Clinics in liver disease”. 14 (1), s. 169–176, luty 2010. PMID: 20123448.
RA Pondé, A. Mikhaĭlova. Hidden hazards of HCV transmission. „Medical microbiology and immunology”. 200 (1), s. 7–11, luty 2011. PMID: 20461405.
X Xia, J. Luo, J. Bai, R. Yu. Epidemiology of HCV infection among injection drug users in China: systematic review and meta-analysis. „Public health”. 122 (10), s. 990–1003, październik 2008. DOI: 10.1016/j.puhe.2008.01.014. PMID: 18486955.
JC Imperial. Chronic hepatitis C in the state prison system: insights into the problems and possible solutions. „Expert review of gastroenterology & hepatology”. 4 (3), s. 355–364, czerwiec 2010. PMID: 20528122.
M FM.F.VescioM FM.F. i inni, Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis, „Journal of epidemiology and community health”, 62 (4), 2008, s. 305–13, DOI: 10.1136/jech.2006.051599, PMID: 18339822.
Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission?. „Hepatology”. 52 (4), s. 1497–1505, czerwiec 2010. DOI: 10.1002/hep.23808. PMID: 20635398.
Lock G, Dirscherl M, Obermeier F, et al.. Hepatitis C –contamination of toothbrushes: myth or reality?. „J. Viral Hepat.”. 13 (9), s. 571–573, wrzesień 2006. DOI: 10.1111/j.1365-2893.2006.00735.x. PMID: 16907842.
NC Lam, PB Gotsch, RC Langan. Caring for pregnant women and newborns with hepatitis B or C. „American family physician”. 82 (10), s. 1225–1229, 2010-11-15. PMID: 21121533.
Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. „Advances in Experimental Medicine and Biology”. 554, s. 211–216, 2004. PMID: 15384578.
V Senadhi. A paradigm shift in the outpatient approach to liver function tests. „Southern medical journal”. 104 (7), s. 521–525, lipiec 2011. PMID: 21886053.
J Halliday, P. Klenerman, E. Barnes. Vaccination for hepatitis C virus: closing in on an evasive target. „Expert review of vaccines”. 10 (5), s. 659–672, maj 2011. DOI: 10.1586/erv.11.55. PMID: 21604986.
H Hagan, Pouget, ER, Des Jarlais, DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. „The Journal of infectious diseases”. 204 (1), s. 74–83, 2011-07-01. PMID: 21628661.
J Torresi, D. Johnson, H. Wedemeyer. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. „Journal of hepatology”. 54 (6), s. 1273–1285, czerwiec 2011. DOI: 10.1016/j.jhep.2010.09.040. PMID: 21236312.
JA Ilyas, JM Vierling. An overview of emerging therapies for the treatment of chronic hepatitis C. „Clinics in liver disease”. 15 (3), s. 515–536, sierpień 2011. PMID: 21867934.
Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. „Ann Pharmacother”. 45 (9), s. 1085–1093, wrzesień 2011. DOI: 10.1345/aph.1P744. PMID: 21828346.
Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. „Ann Pharmacother”. 45 (5), s. 639–648, maj 2011. DOI: 10.1345/aph.1P430. PMID: 21558488.
Ghany MG, Nelson DR, Strader DB, Thomas DL i inni. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. „Hepatology”. 54 (4), s. 1433–1444, październik 2011. DOI: 10.1002/hep.24641. PMID: 21898493. PMCID: PMC3229841.
J Liu, E. Manheimer, K. Tsutani, C. Gluud. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. „The American journal of gastroenterology”. 98 (3), s. 538–544, marzec 2003. PMID: 12650784.
A Rambaldi, BP Jacobs, C. Gluud. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. „Cochrane database of systematic reviews (Online)”, s. CD003620, 2007-10-17. PMID: 17943794.
Fung J, Lai CL, Hung I, et al.. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. „The Journal of Infectious Diseases”. 198 (6), s. 808–812, wrzesień 2008. DOI: 10.1086/591252. PMID: 18657036.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. „Science”. 244 (4902), s. 359–362, kwiecień 1989. DOI: 10.1126/science.2523562. PMID: 2523562.
Kuo G, Choo QL, Alter HJ, et al.. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. „Science”. 244 (4902), s. 362–364, kwiecień 1989. DOI: 10.1126/science.2496467. PMID: 2496467.
team Eurosurveillance editorial. World Hepatitis Day 2011. „Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin”. 16 (30), 2011-07-28. PMID: 21813077.
JB Wong. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. „PharmacoEconomics”. 24 (7), s. 661–672, 2006. PMID: 16802842.
J Ahn, SL Flamm. Hepatitis C therapy: other players in the game. „Clinics in liver disease”. 15 (3), s. 641–656, sierpień 2011. DOI: 10.1016/j.cld.2011.05.008. PMID: 21867942.
J Vermehren, C. Sarrazin. New HCV therapies on the horizon. „Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases”. 17 (2), s. 122–134, luty 2011. PMID: 21087349.